With respect to the immune response, RT can promote the release of tumor neoantigens and inflammatory cytokines, recruit effector T cells to the tumor site, and activate the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway, laying the foundation for RT in combination with immunotherapies [226]. The gene discussed is CGAS; the disease is neoplasm.